Endometrial surveillance in tamoxifen users: Role, timing and accuracy of hysteroscopic investigation: Observational longitudinal cohort study

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages 455-462

  Saccardi, Carlo ^a   Gizzo, Salvatore ^a   Patrelli, Tito Silvio ^b   Ancona, Emanuele ^a   Anis, Omar ^a   Di Gangi, Stefania ^a   Vacilotto, Antonio ^a   D'Antona, Donato ^a   Nardelli, Giovanni Battista ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Endometrial surveillance; Follow up; Hysteroscopy; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL FEATURE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT INDICATION; UTERUS BLEEDING;

ADJUVANT THERAPY; BREAST CANCER; ENDOMETRIAL SURVEILLANCE; FOLLOW-UP; HYSTEROSCOPY; TAMOXIFEN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; HYSTEROSCOPY; LONGITUDINAL STUDIES; MIDDLE AGED; TAMOXIFEN;

EID: 84882737798     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0020     Document Type: Article

References (45)

1. Achiron R, Lipitz S, Sivan E, Goldenberg M, Horovitz A, Frenkel Y & Mashiach S 1995 Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound in Obstetrics & Gynecology 6 116-120. (doi:10.1046/j.1469-0705. 1995.06020116.x)
2. Aebi S, Davidson T, Gruber G, Cardoso F & ESMO Guidelines Working Group 2011 Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 22 (Suppl 6) vi12-vi24. (doi:10.1093/annonc/mdr371)
3. Althuis MD, Sexton M, Langenberg P, Bush TL, Tkaczuk K, Magaziner J & Khoo L 2000 Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. Cancer 89 800-810. (doi:10.1002/1097-0142(20000815)89:4〈800::AID-CNCR12〉3.0.CO;2-Y)
4. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice 2006 ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstetrics and Gynecology 107 1475-1478. (doi:10.1097/00006250- 200606000-00057)
5. Association of Breast Surgery at Baso 2009 Surgical guidelines for the management of breast cancer. European Journal of Surgical Oncology 35 (Suppl 1) 1-22. (doi:10.1016/j.ejso.2009.01.008)
6. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ et al. 2005 Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 353 1784-1792. (doi:10.1056/NEJMoa050518)
7. Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, Cusimano E, Guido T, Nicolò G & Rosso R 1998 Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Research and Treatment 47 41-46. (doi:10.1023/A:1005820115535)
8. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ et al. 2010 Breast cancer risk reduction. Journal of the National Comprehensive Cancer Network 8 1112-1146.
9. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R & Col NF 2003 Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine 18 937-947. (doi:10.1046/j.1525-1497.2003. 20724.x)
10. Bronz L 2000 Hysteroscopy in the assessment of postmenopausal bleeding. Contributions to Gynecology and Obstetrics 20 51-59.
11. Ceci O, Bettocchi S, Nappi L, Di Venere R, Pansini MV & Di Fazio F 2003 Comparison of hysteroscopic and hysterectomy findings to assess the diagnostic accuracy of office hysteroscopy in tamoxifen-treated patients with breast cancer. Journal of the American Association of Gynecologic Laparoscopists 10 392-395. (doi:10.1016/S1074-3804(05)60270-8)
12. Cheng WF, Lin HH, Torng PL & Huang SC 1997 Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecologic Oncology 66 233-237. (doi:10.1006/gyno.1997.4739)
13. Clarke MJ 2008 WITHDRAWN: tamoxifen for early breast cancer. Cochrane Database of Systematic Reviews CD000486. (doi:10.1002/14651858.CD000486)
14. Cohen I 2004 Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecologic Oncology 94 256-266. (doi:10.1016/j.ygyno.2004. 03.048)
15. Curtis RE, Freedman DM, Sherman ME & Fraumeni JF, Jr 2004 Risk of malignant mixed Müllerian tumors after tamoxifen therapy for breast cancer. Journal of the National Cancer Institute 96 70-74. (doi:10.1093/jnci/djh007)
16. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T & IBIS investigators 2002 First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 817-824. (doi:10.1016/S0140-6736(02)09962-2)
17. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B & Costa A 1996 Effect of tamoxifen on endometrial proliferation. Journal of Clinical Oncology 14 434-440. (Pubitemid 26051004)
18. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G & Penault-Llorca F 2000 Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecologic Oncology 78 181-186. (doi:10.1006/gyno.2000.5859)
19. Dijkhuizen FP, Brölmann HA, Oddens BJ, Roumen RM, Coebergh JW & Heintz AP 1996 Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas 25 45-50. (doi:10.1016/0378-5122(96)01043-2)
20. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M et al. 2010 Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology 28 509-518. (doi:10.1200/JCO.2009.23.1274)
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C et al. 2011 Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378 771-784. (doi:10.1016/S0140-6736(11)60993-8)
22. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG et al. 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 97 1652-1662. (doi:10.1093/jnci/dji372)
23. Fong K, Causer P, Atri M, Lytwyn A & Kung R 2003 Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. Radiographics 23 137-150 (discussion 151-155). (doi:10.1148/rg.231025048)
24. Fung MF, Reid A, Faught W, Le T, Chenier C, Verma S, Brydon E & Fung KF 2003 Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecologic Oncology 91 154-159. (doi:10.1016/S0090-8258(03)00441-4)
25. Gao WL, Zhang LP & Feng LM 2011 Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen. Chinese Medical Journal 124 2335-2339.
26. Garuti G, Sambruni I, Cellani F, Garzia D, Alleva P & Luerti M 1999 Hysteroscopy and transvaginal ultrasonography in postmenopausal women with uterine bleeding. International Journal of Gynaecology and Obstetrics 65 25-33. (doi:10.1016/S0020-7292(98)00224-0)
27. Garuti G, Cellani F, Grossi F, Colonnelli M, Centinaio G & Luerti M 2002 Saline infusion sonography and office hysteroscopy to assess endometrial morbidity associated with tamoxifen intake. Gynecologic Oncology 86 323-329. (doi:10.1006/gyno.2002.6783)
28. Giorda G, Crivellari D, Veronesi A, Perin T, Campagnutta E, Carbone A & Scarabelli C 2002 Comparison of ultrasonography, hysteroscopy, and biopsy in the diagnosis of endometrial lesions in postmenopausal tamoxifen-treated patients. Acta Obstetricia et Gynecologica Scandinavica 81 975-980. (doi:10.1034/j.1600-0412.2002.811013.x)
29. Goldstein SR 2010 Modern evaluation of the endometrium. Obstetrics and Gynecology 116 168-176. (doi:10.1097/AOG.0b013e3181dfd557)
30. Guruwadayarhalli B, Jones SE & Srinivasan V 2007 Hysteroscopy in the diagnosis of postmenopausal bleeding. Menopause International 13 132-134. (doi:10.1258/175404507781605587)
31. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. 2010 American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology 28 2784-2795. (doi:10.1200/JCO.2009.25. 6529)
32. Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I & Narod SA 2012 Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treatment Reviews 38 318-328. (doi:10.1016/j.ctrv.2011.06.009)
33. Litta P, Merlin F, Saccardi C, Pozzan C, Sacco G, Fracas M, Capobianco G & Dessole S 2005 Role of hysteroscopy with endometrial biopsy to rule out endometrial cancer in postmenopausal women with abnormal uterine bleeding. Maturitas 50 117-123. (doi:10.1016/j.maturitas.2004.05.003)
34. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P & Dixon JM 1999 Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. Journal of Clinical Oncology 17 2050-2054. (Pubitemid 29318834)
35. Neis KJ, Brandner P & Schlenker M 2000 Tamoxifen-induced hyperplasia of the endometrium. Contributions to Gynecology and Obstetrics 20 60-68.
36. Osborne CK 1998 Tamoxifen in the treatment of breast cancer. New England Journal of Medicine 339 1609-1618. (doi:10.1056/NEJM199811263392207)
37. Pérez-Medina T, Salazar FJ, San-Frutos L, Ríos M, Jiménez JS, Troyano J, Cayuela E & Iglesias E 2011 Hysteroscopic dynamic assessment of the endometrium in patients treated with long-term tamoxifen. Journal of Minimally Invasive Gynecology 18 349-354. (doi:10.1016/j.jmig.2010.12.014)
38. Polin SA & Ascher SM 2008 The effect of tamoxifen on the genital tract. Cancer Imaging 8 135-145. (doi:10.1102/1470-7330.2008.0020)
39. Ramondetta LM, Sherwood JB, Dunton CJ & Palazzo JP 1999 Endometrial cancer in polyps associated with tamoxifen use. American Journal of Obstetrics and Gynecology 180 340-341. (doi:10.1016/S0002-9378(99)70210-3)
40. Seoud M, Shamseddine A, Khalil A, Salem Z, Saghir N, Bikhazi K, Bitar N, Azar G & Kaspar H 1999 Tamoxifen and endometrial pathologies: a prospective study. Gynecologic Oncology 75 15-19. (doi:10.1006/gyno.1999.5519)
41. Siegel R, Ward E, Brawley O & Jemal A 2011 Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians 61 212. (doi:10.3322/caac. 20121)
42. Taponeco F, Curcio C, Fasciani A, Giuntini A, Artini PG, Fornaciari G, Petraglia F & Genazzani AR 2002 Indication of hysteroscopy in tamoxifen treated breast cancer patients. Journal of Experimental & Clinical Cancer Research 21 37-43. (Pubitemid 34309230)
43. The national Comprehensive Cancer Network - NCCN Breast cancer guidelines v1.2011. (downloaded from: http://www.nccn.org/professionals/physician-gls/f- guidelines.asp).
44. Tinelli R, Tinelli FG, Cicinelli E, Malvasi A & Tinelli A 2008 The role of hysteroscopy with eye-directed biopsy in postmenopausal women with uterine bleeding and endometrial atrophy. Menopause 15 737-742. (doi:10.1097/gme.0b013e31815b644e)
45. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L & Runowicz CD 2002 Association of tamoxifen and uterine sarcoma. Journal of Clinical Oncology 20 2758-2760.